Assenagon Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Assenagon Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-347,961	Closed	-$31.6M	–	1503
2023 Q1	$31.6M	Buy	+347,961	New	+$20.4M	0.11%	161
2022 Q1	–	Sell	-172,323	Closed	-$4.54M	–	1593
2021 Q4	$4.54M	Buy	+172,323	New	+$13.3M	0.01%	544
2020 Q2	–	Sell	-31,463	Closed	-$4.54M	–	1273
2020 Q1	$4.54M	Sell	31,463 -5,842	-16%	-$1.13M	0.04%	240
2019 Q4	$7.63M	Buy	+37,305	New	+$6.81M	0.05%	204

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Assenagon Asset Management's RETA Position: Q2 2023 in Review

Assenagon Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 347,961 shares — an estimated $31.6M sold.

Assenagon Asset Management first reported a position in RETA in Q4 2019 and held it in 4 quarters. The position peaked at $31.6M in Q1 2023. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Assenagon Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Assenagon Asset Management sold 347,961 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $31.6M.
Assenagon Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 4 quarters.
Assenagon Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $31.6M in Q1 2023.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Assenagon Asset Management's 13F filing for Q2 2023, filed 25 Jul 2023.